Biomerica Inc is a bioscience company that focuses on developing and providing innovative diagnostic products for the healthcare industry. The company specializes in the research and development of tests that help in the early detection of diseases and conditions, with a particular emphasis on gastrointestinal health, autoimmune diseases, and food intolerances. By leveraging advanced technology and scientific expertise, Biomerica aims to improve patient outcomes and enhance the efficiency of medical diagnostics, making valuable contributions to the fields of preventive medicine and personalized healthcare. Read More
Synergy CHC Corp. (NASDAQ: SNYR), a consumer health and wellness company, has reported its financial results for Q2 2025, marking its tenth consecutive quarter of profitability . The company posted revenue of $8.1 million, gross margin of 76.7%, and net income of $1.5 million—up 125% year-over-year—with earnings per share rising 86% to $0.17. EBITDA surged 136% to $3.8 million. See Entire Press Release.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.
The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.
Biomerica (NASDAQ: BMRA), a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agreement is related to BMRA common stock shares. The company filed a prospectus supplement on May 10, 2024. EF Hutton is serving as sales agent to Biomerica in connection with the $5.5 million at-the-market offering. “In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock pursuant to this prospectus having an aggregate offering price of up to $5,500,000 from time to time through or to the sales agents, acting as sales agents or principals,” stated the company in the prospectus.
